MedTrace Logo

Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study

NCT05794412 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2025-01-14

No results posted yet for this study

Summary

The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with SARS-CoV-2, influenza virus and RSV. The investigators will include app. 320 participants which will be followed for up to 17 months. During this time, the investigators will monitor their nasal mucosal antibodies at regular intervals and compare them to their infectious viral load if they are infected with SARS-CoV-2, influenza virus or RSV. Participants are invited to take a test for SARS-CoV-2, influenza virus or RSV in case of respiratory symptoms. If participants are positive the investigators will follow their viral load kinetics by taking nasopharyngeal swabs every 2-3 days. The investigators will also record the duration and strength of the following symptoms:

* Cough
* Fever
* Tired
* Sore throat
* Difficulty breathing
* Respiratory distress
* Headache
* Loss (or alteration) of smell
* Loss (or alteration) of sense of taste
* Myalgias
* Chills
* Subjective fever
* Pink sputum (or coughing up blood)
* Thoracic pain
* Runny nose
* Abdominal pain
* Nausea
* Vomiting
* Diarrhea
* Constipation
* Irritated or watery eyes
* Rashes
* Other

Conditions

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • University of Geneva, Switzerland

    collaborator OTHER

  • ModernaTX, Inc.

    collaborator INDUSTRY

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Benjamin Meyer, Dr. · University of Geneva

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-10
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05794412 on ClinicalTrials.gov